Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
40.68
-1.40 (-3.33%)
At close: Aug 18, 2026, 4:00 PM EDT
41.18
+0.50 (1.23%)
After-hours: Aug 18, 2026, 7:34 PM EDT
Veracyte Revenue
Veracyte had revenue of $150.32M in the quarter ending June 30, 2026, with 15.49% growth. This brings the company's revenue in the last twelve months to $561.90M, up 17.28% year-over-year. In the year 2025, Veracyte had annual revenue of $517.15M with 16.01% growth.
Revenue (ttm)
$561.90M
Revenue Growth
+17.28%
P/S Ratio
5.82
Revenue / Employee
$744,238
Employees
755
Market Cap
3.27B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 517.15M | 71.38M | 16.01% |
| Dec 31, 2024 | 445.76M | 84.71M | 23.46% |
| Dec 31, 2023 | 361.05M | 64.52M | 21.76% |
| Dec 31, 2022 | 296.54M | 77.02M | 35.09% |
| Dec 31, 2021 | 219.51M | 102.03M | 86.85% |
| Dec 31, 2020 | 117.48M | -2.89M | -2.40% |
| Dec 31, 2019 | 120.37M | 28.36M | 30.82% |
| Dec 31, 2018 | 92.01M | 20.06M | 27.87% |
| Dec 31, 2017 | 71.95M | 6.87M | 10.55% |
| Dec 31, 2016 | 65.09M | 15.58M | 31.48% |
| Dec 31, 2015 | 49.50M | 11.31M | 29.62% |
| Dec 31, 2014 | 38.19M | 16.31M | 74.51% |
| Dec 31, 2013 | 21.88M | 10.26M | 88.20% |
| Dec 31, 2012 | 11.63M | 8.98M | 339.62% |
| Dec 31, 2011 | 2.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 2.27B |
| Sotera Health Company | 1.22B |
| NeoGenomics | 766.30M |
| CareDx | 458.09M |
| GeneDx Holdings | 454.43M |
| Twist Bioscience | 431.80M |
| BillionToOne | 397.41M |
| Adaptive Biotechnologies | 308.08M |
VCYT News
- 7 days ago - Veracyte Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 14 days ago - Veracyte price target lowered to $44 from $47 at Morgan Stanley - TheFly
- 14 days ago - Veracyte price target lowered to $55 from $68 at Stephens - TheFly
- 14 days ago - Veracyte price target lowered to $54 from $66 at Piper Sandler - TheFly
- 15 days ago - Veracyte price target lowered to $50 from $60 at Canaccord - TheFly
- 18 days ago - Veracyte falls -24.1% - TheFly
- 18 days ago - Veracyte falls -24.0% - TheFly
- 18 days ago - Veracyte price target raised to $69 from $57 at Needham - TheFly